HomeCompareERYP vs PEP

ERYP vs PEP: Dividend Comparison 2026

ERYP yields 256.41% · PEP yields 3.63%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ERYP wins by $541.08M in total portfolio value
10 years
ERYP
ERYP
● Live price
256.41%
Share price
$0.78
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$541.22M
Annual income
$306,262,465.48
Full ERYP calculator →
PEP
PepsiCo Inc.
● Live price
3.63%
Share price
$156.82
Annual div
$5.69
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$141.9K
Annual income
$61,875.67
Full PEP calculator →

Portfolio growth — ERYP vs PEP

📍 ERYP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodERYPPEP
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ERYP + PEP cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ERYP pays
PEP pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ERYP
Annual income on $10K today (after 15% tax)
$21,794.87/yr
After 10yr DRIP, annual income (after tax)
$260,323,095.66/yr
PEP
Annual income on $10K today (after 15% tax)
$308.41/yr
After 10yr DRIP, annual income (after tax)
$52,594.32/yr
At 15% tax rate, ERYP beats the other by $260,270,501.34/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ERYP + PEP for your $10,000?

ERYP: 50%PEP: 50%
100% PEP50/50100% ERYP
Portfolio after 10yr
$270.68M
Annual income
$153,162,170.58/yr
Blended yield
56.58%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PEP right now

ERYP
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
1.9
Piotroski
2/9
PEP
Analyst Ratings
1
Strong
15
Buy
27
Hold
1
Sell
Consensus: Hold
Price Target
$172.43
+10.0% upside vs current
Range: $156.00 — $191.00
Altman Z
3.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ERYP buys
0
PEP buys
0
No recent congressional trades found for ERYP or PEP in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricERYPPEP
Forward yield256.41%3.63%
Annual dividend / share$2.00$5.69
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$541.22M$141.9K
Annual income after 10y$306,262,465.48$61,875.67
Total dividends collected$516.37M$123.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold

Year-by-year: ERYP vs PEP ($10,000, DRIP)

YearERYP PortfolioERYP Income/yrPEP PortfolioPEP Income/yrGap
1← crossover$36,341$25,641.03$10,849$509.42+$25.5KERYP
2$125,971$87,086.09$11,969$750.47+$114.0KERYP
3$416,912$282,122.92$13,500$1,124.14+$403.4KERYP
4$1,318,722$872,626.36$15,680$1,721.66+$1.30MERYP
5$3,990,640$2,579,607.07$18,929$2,715.34+$3.97MERYP
6$11,565,551$7,295,566.53$24,023$4,450.80+$11.54MERYP
7$32,135,691$19,760,551.21$32,510$7,669.92+$32.10MERYP
8$85,699,274$51,314,084.97$47,709$14,093.60+$85.65MERYP
9$219,589,910$127,891,686.63$77,415$28,083.48+$219.51MERYP
10$541,223,669$306,262,465.48$141,922$61,875.67+$541.08MERYP

ERYP vs PEP: Complete Analysis 2026

ERYPStock

ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.

Full ERYP Calculator →

PEPConsumer Staples

PepsiCo, Inc. manufactures, markets, distributes, and sells various beverages and convenient foods worldwide. The company operates through seven segments: Frito-Lay North America; Quaker Foods North America; PepsiCo Beverages North America; Latin America; Europe; Africa, Middle East and South Asia; and Asia Pacific, Australia and New Zealand and China Region. It provides dips, cheese-flavored snacks, and spreads, as well as corn, potato, and tortilla chips; cereals, rice, pasta, mixes and syrups, granola bars, grits, oatmeal, rice cakes, simply granola, and side dishes; beverage concentrates, fountain syrups, and finished goods; ready-to-drink tea, coffee, and juices; dairy products; and sparkling water makers and related products. It serves wholesale and other distributors, foodservice customers, grocery stores, drug stores, convenience stores, discount/dollar stores, mass merchandisers, membership stores, hard discounters, e-commerce retailers and authorized independent bottlers, and others through a network of direct-store-delivery, customer warehouse, and distributor networks, as well as directly to consumers through e-commerce platforms and retailers. The company was founded in 1898 and is headquartered in Purchase, New York.

Full PEP Calculator →
📬

Get this ERYP vs PEP comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ERYP vs SCHDERYP vs JEPIERYP vs OERYP vs KOERYP vs MAINERYP vs MOERYP vs PMERYP vs GIS

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.